Kalamazoo Firm Presents Clinical Trial Results Of Alzheimer's DrugMetabolic Solutions Development Co. LLC announced that Jerry Colca, co-founder and chief scientific officer of MSDC, presented results of a Phase 2a study at the 14th International Conference on Alzheimer's Drug Discovery.
Kalamazoo Company Announces New Drug Target For DiabetesMetabolic Solutions Development Co. LLC announced Wednesday the publication of data in the latest issue of the scientific journal PLOS ONE on a new drug target for treating type 2 diabetes by boosting the body's sensitivity to insulin.
Officials: Diabetes Breakthrough Shows Value Of Life Science IncubatorsBreakthrough research by Metabolic Solutions Development Co., including data published Wednesday on a new drug target for type 2 diabetes, underscores the key role a quality life sciences incubator can play, according to southwest Michigan life science leaders.
New Treatment Possible For Type 2 DiabetesA study published online in the Journal of Biological Chemistry showed a new drug to treat diabetes being developed by Metabolic Solutions Development Co. LLC, MSDC-0602, improved insulin resistance and inflammation in obese mice.
Kalamazoo Pharma Startup To Present At Diabetes Conference
Metabolic Solutions Launches New Trial Of Diabetes DrugKalamazoo-based Metabolic Solutions Development Co., a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced Tuesday that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.
Kalamazoo Pharma Firm To Present Advance In Obesity Treatment